PharmaPoint: Psoriasis – Global Drug Forecast and Market Analysis to 2024

Psoriasis (PsO) is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 2-3% worldwide. Specifically, adult plaque psoriasis, the most common form of Psoriasis, is the focus of this report. Although not life-threatening, Psoriasis causes tremendous morbidity and personal angst for patients.

GlobalData projects the psoriasis market in 8MM to experience modest growth during the forecast period at a CAGR of 7.26%. This growth will be driven primarily by the highly anticipated arrivals of promising systemic therapies- interleukin-23 (IL-23) inhibitors (guselkumab and tildrakizumab), interleukin-17 (IL-17) inhibitors (Cosentyx, Taltz, and brodalumab) as well as phsophodiesterase (PDE4) inhibitor- Otezla (apremilast). Nevertheless, looming patent expiries of high-grossing branded drugs- especially TNF inhibitors, Humira, Enbrel and Remicade, in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with rapid global developments of biosimilars , are expected to spread the growth throughout the different classes of products, away from the branded TNF inhibitors which have traditionally been the main driver of growth in the prior years.

Scope

Overview of Psoriasis, including epidemiology, etiology, pathophysiology, symptoms and current treatment options

Topline Psoriasis market revenue from 2014–2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

Key topics covered include strategic competitor assessment, unmet needs, pipeline assessment, and market outlook for the Psoriasis market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products- including promising IL-17 and IL-23 inhibitors.

Analysis of the current and future market competition in the global Psoriasis market (8MM). Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

How good is the management of Psoriasis with marketed therapies?

Which drugs and players are important in the current management landscape?

What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the Psoriasis market?

What are the significant unmet needs and remaining opportunities in the Psoriasis market?

What clinical and commercial factors are likely to uptake of Psoriasis therapies in the US, 5EU, Japan and India?

Companies mentioned

Amgen

AbbVie

Can-Fite Biopharma

Celgene

Eli Lilly

Johnson & Johnson

LEO Pharma

Merck

Novartis

Pfizer

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.2Symptoms

4Epidemiology

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1Prevalence

4.4Forecast Methodology

4.4.1Sources Used for One-Year Diagnosed Prevalence of Psoriasis

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods, One-Year Diagnosed Prevalent Cases of Psoriasis

4.5Epidemiological Forecast for Psoriasis (2014–2024)

4.5.1One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.2Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.3Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.4Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis

4.5.5One-Year Diagnosed Prevalent Cases of Psoriasis by Severity

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Disease Management

5.1Diagnosis and Treatment Overview

5.1.1Diagnosis

5.1.2Leading Prescribed Drugs and Treatment Guidelines

5.1.3Clinical Practice

5.2US

5.35EU

5.4Japan

5.5India

6Competitive Assessment

6.1Overview

6.2Strategic Competitor Assessment

6.3Product Profiles – Major Brands

6.3.1Enbrel (Etanercept)

6.3.2Humira (Adalimumab)

6.3.3Remicade (Infliximab)

6.3.4Stelara (Ustekinumab)

6.3.5Cosentyx (Secukinumab)

6.3.6Taltz (Ixekizumab)

6.3.7Otezla (Apremilast)

6.3.8Taclonex and Enstilar (Calcipotriene and Betamethasone Dipropionate)

6.3.9Methotrexate

6.3.10Fumaderm (Fumaric Acid Esters)

6.3.11Alzumab (Itolizumab)

6.3.12Other Therapeutic Drug Classes Used in Psoriasis

6.3.13Non-pharmacological Therapy

7Unmet Need and Opportunity

7.1Overview

7.2Limited Patient Access Due to Drug Reimbursement Pattern

7.2.1Unmet Need

7.2.2Gap Analysis

7.2.3Opportunity

7.3Improved Drug Safety and Efficacy Profiles

7.3.1Unmet Need

7.3.2Gap Analysis

7.3.3Opportunity

7.4Education and Treatment of Psychological Factors Accompanying Psoriasis

7.4.1Unmet Need

7.4.2Gap Analysis

7.4.3Opportunity

7.5Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis

7.5.1Unmet Need

7.5.2Gap Analysis

7.5.3Opportunity

8Pipeline Assessment

8.1Overview

8.2Clinical Trial Mapping

8.2.1Clinical Trials by Country

8.3Clinical Trials by Phase and Trial Status

8.4Promising Drugs in Clinical Development

8.4.1Xeljanz (Tofacitinib)

8.4.2Brodalumab

8.4.3Guselkumab (CNTO-1959)

8.4.4Tildrakizumab

8.4.5Piclidenoson (CF-101)

8.4.6Additional Phase III Pipeline Products

8.4.7Phase II Pipeline Products

8.4.8Phase I Pipeline Products

8.5Biosimilar Pipeline Products

8.5.1Introduction

8.5.2Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases

8.5.3Biosimilars in the Immunology Community

8.5.4By the Numbers: Biosimilars in Development

8.5.5The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

8.5.6Uptake of Biosimilars for Psoriasis is Expected to Vary by Market

8.5.7Biosimilars Forecast

9Current and Future Players

9.1Overview

9.2Trends in Corporate Strategy

9.3Company Profiles

9.3.1Johnson & Johnson

9.3.2AbbVie

9.3.3Amgen

9.3.4Novartis

9.3.5Pfizer

9.3.6Eli Lilly

9.3.7Merck

9.3.8LEO Pharma

9.3.9Celgene

9.3.10Can-Fite Biopharma

10Market Outlook

10.1Global Markets

10.1.1Forecast

10.1.2Drivers and Barriers – Global Issues

10.2US

10.2.1Forecast

10.2.2Key Events

10.2.3Drivers and Barriers

10.35EU

10.3.1Forecast

10.3.2Key Events

10.3.3Drivers and Barriers

10.4Japan

10.4.1Forecast

10.4.2Key Events

10.4.3Drivers and Barriers

10.5India

10.5.1Forecast

10.5.2Key Events

10.5.3Drivers and Barriers

11Appendix

11.1Bibliography

11.2Abbreviations

11.3Methodology

11.4Forecasting Methodology

11.4.1Diagnosed Psoriasis Patients

11.4.2Percent Drug-Treated Patients

11.4.3Drugs Included in Each Therapeutic Class

11.4.4Launch and Patent Expiry Dates

11.4.5General Pricing Assumptions

11.4.6Individual Drug Assumptions

11.4.7Generic Erosion

11.4.8Pricing of Pipeline agents

11.5Physicians and Specialists Included in this Study

11.6Primary Research – Prescriber Survey

11.7About the Authors

11.7.1Author

11.7.2Reviewer

11.7.3Epidemiologist

11.7.4Global Director of Therapy Analysis and Epidemiology

11.7.5Global Head of Healthcare

11.8About GlobalData

11.9Contact Us

11.10Disclaimer

List of Tables

Table 1: Immune Cells Involved in Lesions

Table 2: Symptoms of Psoriasis

Table 3: Risk Factors and Comorbidities for Psoriasis

Table 4: 8MM, Global Trends for the Diagnosed Prevalence of Psoriasis

Table 5: 8MM, Sources of Epidemiological Data Used for the Forecast for Psoriasis One-Year Diagnosed Prevalent Cases

Table 6: 8MM, Sources of Epidemiological Data Used for the Segmentation of One-Year Diagnosed Prevalent Cases of Psoriasis by Severity

Table 7: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014–2024

Table 8: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N (Row %), 2014

Table 9: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N (Row %), 2014

Table 10: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis

Table 11: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2014

Table 12: Treatment Guidelines for Psoriasis

Table 13: Country Profile – US

Table 14: Country Profile – 5EU

Table 15: Country Profile – Japan

Table 16: Country Profile – India

Table 17: Leading Treatments for Psoriasis, 2015

Table 18: Product Profile – Enbrel

Table 19: Enbrel Pivotal Study I Outcomes at 3 and 6 Months

Table 20: Enbrel pivotal study II outcomes at 3 Months

Table 21: Long-Term Studies on Enbrel Efficacy in Treatment of Psoriasis

Table 22: Long-Term Safety Profile of Enbrel in the Treatment of Psoriasis

Table 23: Enbrel SWOT Analysis, 2015

Table 24: Global Sales Forecast ($m) for Enbrel, 2014–2024

Table 25: Product Profile – Humira

Table 26: Humira pivotal study outcomes at 16 weeks

Table 27: Humira SWOT Analysis, 2015

Table 28: Global Sales Forecast ($m) for Humira, 2014–2024

Table 29: Product Profile – Remicade

Table 30: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26

Table 31: Safety Results and AEs of RESTORE1 Trial of Remicade vs. MTX at Week 16

Table 32: Remicade SWOT Analysis, 2015

Table 33: Global Sales Forecast ($m) for Remicade, 2014–2024

Table 34: Product Profile – Stelara

Table 35: Stelara Pivotal Study Outcomes at Week 12

Table 36: Stelara SWOT Analysis, 2015

Table 37: Global Sales Forecast ($m) for Stelara, 2014–2024

Table 38: Product Profile – Cosentyx

Table 39: Efficacy Endpoints in Cosentyx Phase III ERASURE Study

Table 40: Efficacy End Points in Cosentyx Phase III FIXTURE study

Table 41: Cosentyx SWOT Analysis, 2015

Table 42: Global Sales Forecast ($m) for Cosentyx, 2014–2024

Table 43: Product Profile – Taltz

Table 44: Efficacy Results of UNCOVER-2 at Week 12

Table 45: Efficacy Results of UNCOVER-3 at Week 12

Table 46: Taltz SWOT Analysis, 2015

Table 47: Global Sales Forecast ($m) for Taltz, 2014–2024

Table 48: Product Profile – Otezla

Table 49: Otezla Efficacy Results at Week 16 in Studies ESTEEM-1 and ESTEEM-2

Table 50: Otezla SWOT Analysis, 2015

Table 51: Global Sales Forecast ($m) for Otezla, 2014–2024

Table 52: Product Profile – Taclonex/Enstilar

Table 53: Taclonex Efficacy Outcomes from Pivotal Phase III Studies for Adult Scalp and Body Psoriasis.

Table 54: Taclonex/Enstilar SWOT Analysis, 2015

Table 55: Global Sales Forecast ($m) for Taclonex/Daivobet/Dovobet, 2014–2024

Table 56: Product Profile – Methotrexate

Table 57: Methotrexate SWOT Analysis, 2015

Table 58: Global Sales Forecast ($m) for Methotrexate, 2014–2024

Table 59: Product Profile – Fumaderm

Table 60: Fumaderm SWOT Analysis, 2015

Table 61: Global Sales Forecast ($m) for Fumaderm, 2014–2024

Table 62: Product Profile – Alzumab

Table 63: Alzumab SWOT Analysis, 2013

Table 64: Global Sales Forecast ($m) for Alzumab, 2014–2024

Table 65: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2015

Table 66: Dosing Guidelines for Broadband Ultraviolet B

Table 67: Dosing Guidelines for Narrowband Ultraviolet B

Table 68: Overall Unmet Needs in Psoriasis – Current Level of Attainment

Table 69: Psoriasis – Clinical Trials by Phase and Status, 2015

Table 70: Psoriasis – Phase Pipeline, 2015

Table 71: Comparison of Therapeutic Classes in Development for Psoriasis, 2015

Table 72: Product Profile – Xeljanz

Table 73: Xeljanz SWOT Analysis, 2015

Table 74: Global Sales Forecast ($m) for Xeljanz, 2014–2024

Table 75: Product Profile – Brodalumab

Table 76: Brodalumab SWOT Analysis, 2015

Table 77: Global Sales Forecast ($m) for Brodalumab, 2014–2024

Table 78: Product Profile – Guselkumab

Table 79: Guselkumab SWOT Analysis, 2015

Table 80: Global Sales Forecast ($m) for Guselkumab, 2014–2024

Table 81: Product Profile – Tildrakizumab

Table 82: Tildrakizumab SWOT Analysis, 2015

Table 83: Global Sales Forecast ($m) for Tildrakizumab, 2014–2024

Table 84: Product Profile – Piclidenoson (CF-101)

Table 85: Piclidenoson SWOT Analysis, 2015

Table 86: Additional Phase III Psoriasis Pipeline drugs, 2015

Table 87: Phase II Psoriasis Pipeline, 2015

Table 88: Phase I Psoriasis Pipeline, 2015

Table 89: Marketed and Pipeline Biosimilars for Psoriasis in the 8MM, 2015

Table 90: Physician Uptake of Biosimilar Products for Psoriasis Across the 8MM, 2015

Table 91: Global Sales Forecast ($m) for Etanercept Biosimilars, 2014–2024

Table 92: Global Sales Forecast ($m) for Adalimumab Biosimilars, 2014–2024

Table 93: Global Sales Forecast ($m) for Infliximab Biosimilars, 2014–2024

Table 94: Key Companies in the Psoriasis Market, 2015

Table 95: J&J’s Psoriasis Portfolio Assessment, 2015

Table 96: J&J’s Psoriasis Portfolio SWOT Analysis, 2015

Table 97: AbbVie’s Psoriasis Portfolio Assessment, 2015

Table 98: AbbVie’s Psoriasis SWOT Analysis, 2015

Table 99: Amgen’s Psoriasis Portfolio Assessment, 2015

Table 100: Amgen’s Psoriasis SWOT Analysis, 2015

Table 101: Novartis’s Psoriasis Portfolio Assessment, 2015

Table 102: Novartis’ Psoriasis SWOT Analysis, 2015

Table 103: Pfizer’s Psoriasis Portfolio Assessment, 2015

Table 104: Pfizer’s Psoriasis Portfolio SWOT Analysis, 2015

Table 105: Eli Lilly’s Psoriasis Portfolio Assessment, 2015

Table 106: Eli Lilly’s Psoriasis Portfolio SWOT Analysis, 2015

Table 107: Merck’s Psoriasis Portfolio Assessment, 2015

Table 108: Merck’s Psoriasis Portfolio SWOT Analysis, 2015

Table 109: LEO Pharma’s Psoriasis Portfolio Assessment, 2015

Table 110: LEO Pharma’s Psoriasis Portfolio SWOT Analysis, 2015

Table 111: Celgene’s Psoriasis Portfolio Assessment, 2015

Table 112: Celgene’s Psoriasis Portfolio SWOT Analysis, 2015

Table 113: Can-Fite’s Psoriasis Portfolio Assessment, 2015

Table 114: Celgene’s Psoriasis Portfolio SWOT Analysis, 2015

Table 115: Global Sales Forecast ($m) for Psoriasis, 2014–2024

Table 116: Global Psoriasis Market – Drivers and Barriers, 2014–2024

Table 117: Sales Forecast ($) for Psoriasis in the US, 2014–2024

Table 118: Key Events Impacting Sales for Psoriasis in the US, 2014–2024

Table 119: Psoriasis Market in the US – Drivers and Barriers, 2014–2024

Table 120: Sales Forecast ($) for Psoriasis in the 5EU, 2014–2024

Table 121: Key Events Impacting Sales for Psoriasis in the 5EU, 2014–2024

Table 122: Psoriasis Market in the 5EU – Drivers and Barriers, 2014–2024

Table 123: Sales Forecast ($) for Psoriasis in Japan, 2014–2024

Table 124: Key Events Impacting Sales for Psoriasis in Japan, 2014–2024

Table 125: Psoriasis Market in Japan – Drivers and Barriers, 2014–2024

Table 126: Sales Forecast ($) for Psoriasis in India, 2014–2024

Table 127: Key Events Impacting Sales for Psoriasis in India, 2014–2024

Table 128: Psoriasis Market in India – Drivers and Barriers, 2014–2024

Table 129: Key Launch Dates

Table 130: Key Patent Expiries

Table 131: Key Launch Dates

Table 132: Physicians Surveyed, by Country

List of Figures

Figure 1: Psoriatic Plaque on Elbow of Patient

Figure 2: The Three Layers of the Skin and Associated Structures

Figure 3: Healthy Skin Versus Psoriatic Skin

Figure 4: 8MM, One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, All Ages, N, 2014–2024

Figure 5: 8MM, Age-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, Both Sexes, N, 2014

Figure 6: 8MM, Sex-Specific One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, N, 2014

Figure 7: 8MM, Age-Standardized One-Year Diagnosed Prevalent Cases of Psoriasis (%), All Ages, by Sex, 2014

Figure 8: 8MM, Severity Profile of One-Year Diagnosed Prevalent Cases of Psoriasis, All Ages, Both Sexes, N, 2014

Figure 9: Psoriasis Therapeutics – Ongoing Clinical Trial Sites by Country, 2015

Figure 10: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2014–2024

Figure 11: Biosimilar Prescribing Habits in Psoriasis Across the 8MM, 2015

Figure 12: Global Sales Forecast ($m) for Enbrel vs. Etanercept Biosimilars, 2014–2024

Figure 13: Global Sales Forecast ($m) for Humira vs. Adalimumab Biosimilars, 2014–2024

Figure 14: Global Sales Forecast ($m) for Remicade vs. Infliximab Biosimilars, 2014–2024

Figure 15: Company Portfolio Gap Analysis in Psoriasis, 2014–2024

Figure 16: Global Sales for Psoriasis by Region, 2014–2024

Figure 17: Sales for Psoriasis in the US by Drug Class, 2014–2024

Figure 18: Sales for Psoriasis in the 5EU by Drug Class, 2014–2024

Figure 19: Sales for Psoriasis in the 5EU by Region, 2014–2024

Figure 20: Sales for Psoriasis in Japan by Drug Class, 2014–2024

Figure 21: Sales for Psoriasis in India by Drug Class, 2014–2024

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports